NFKB1 and diffuse large B-cell lymphoma: In the present phase I clinical trial, we sought to expand on these findings and determine whether systemic, intravenous administration of NBD peptide is safe and effective in inhibiting constitutive canonical NF-κB signaling in lymphomatous tissue of dogs with spontaneous ABC-like DLBCL.